نتایج جستجو برای: monoclonal anti d

تعداد نتایج: 961388  

Journal: :Bangladesh Journal of Medicine 2022

Background: ABO and Rh blood group antigens are inherited traits ,located on chromosome 1 and19. They usually not altered throughout the life of an individual. Blood grouping consists forward reverse both procedures should match with each other. A discrepancy exists when results do be resolved before transfusion to properly labeled prevent reaction. Methods: prospective study was carried out in...

Journal: :iranian journal of immunology 0
mahmood shams department of hematology, faculty of allied medicine, tehran university of medical sciences mahmood jeddi-tehrani monoclonal antibody research center, avicenna research institute, acecr, tehran, iran farzaneh notash haghighat monoclonal antibody research center, avicenna research institute, acecr, tehran, iran ali ahmad bayat monoclonal antibody research center, avicenna research institute, acecr, tehran, iran jafar mahmoudian monoclonal antibody research center, avicenna research institute, acecr, tehran, iran mohammad reza rezvani department of hematology, faculty of allied medicine, tehran university of medical sciences

background: human cd34 is a transmembrane glycoprotein which is expressed in human hematopoietic stem cells (hscs) and the small- vessel endothelial cells of a variety of tissues. cd34 plays a critical role as a marker for diagnosis and classification of leukemia. anti cd34 antibodies are used for isolation and purification of hscs from bone marrow, peripheral blood and cord blood. objective: t...

Journal: :Archives of Pharmacy Practice 2021

Multiple sclerosis is a common leading cause of disability worldwide. CD20-expressing B cells play major role in multiple pathogenesis. Hence, anti-CD20 monoclonal antibodies effectively deplete mainly by complement-dependent cytotoxicity, antibody-dependent cell-mediated phagocytosis, and cellular cytotoxicity. While the precise etiology remains unknown, it now recognized that environment...

2006
Michael F. Wolf Ulrike Koerner Kurt Schumacher

The Thomsen-Friedenreich antigen (T-antigen) is a cryptic disaccharide structure on human erythrocytes and is supposed to be expressed in an unhidden form on carcinoma cells. We tested the ability of four antiT reagents (i.e., peanut agglutinili, human and rabbit anti-T antisera, and monoclonal anti-T antibodies) to agglutinate neuraminidase treated hu man erythrocytes and compared their capaci...

Journal: :Iranian journal of immunology : IJI 2008
Roya Payam Khaja Pasha Fazel Shokri

RhD antigen is the most immunogenic and clinically significant antigen of red blood cells after ABO system. It has historically been associated with hemolytic disease of the newborn (HDN) which is now routinely prevented by the administration of polyclonal anti-D immunoglobulin. This management of HDN has proven to be one of the most successful cases of prophylactic treatment based on antibody ...

Journal: :Immuno-oncology technology 2022

CD39 is an extracellular ectonucleotidase highly expressed in the tumor microenvironment (TME) that, sequentially with CD73, contributes to production of adenosine (Ado), via hydrolysis triphosphate (ATP). IPH5201 a blocking anti-CD39 monoclonal antibody (mAb) that may promote antitumor immunity by accumulating immunostimulatory ATP released necrotic cells and reducing immunosuppressive Ado lev...

2017
Alex Françoso Patricia Ucelli Simioni

Colorectal cancer is considered a disease of the elderly population. Since the number of geriatric patients continues to rise, monoclonal antibody therapy is the most promising therapy in the recent research. Presently, the monoclonal antibodies most frequently used in the treatment of colorectal tumors are bevacizumab, cetuximab, panitumumab, and ramucirumab. Bevacizumab is a monoclonal antibo...

2017
Haruki Watanabe Katsue S. Watanabe Keyue Liu Sumie Hiramatsu Sonia Zeggar Eri Katsuyama Noriko Tatebe Akiya Akahoshi Fumiaki Takenaka Takahisa Hanada Masaru Akehi Takanori Sasaki Ken-ei Sada Eiji Matsuura Masahiro Nishibori Jun Wada

We evaluated the efficacy of a neutralizing anti-high mobility group box 1 (HMGB1) monoclonal antibody in MRL/lpr lupus-prone mice. The anti-HMGB1 monoclonal antibody (5 mg/kg weight) or class-matched control immunoglobulin G2a (IgG2a) was administered intravenously twice a week for 4-15 weeks. Urine albumin was monitored, and histological evaluation of the kidneys was conducted at 16 weeks. Ly...

پایان نامه :وزارت بهداشت، درمان و آموزش پزشکی - دانشگاه علوم پزشکی اراک - دانشکده علوم پزشکی اراک 1392

در حال حاضر ivig و anti d از درمان های معمول itp می باشند.دربرخی مطالعات تأثیراین دو دارو با هم یکسان بوده و در برخی مطالعات تأثیرات متفاوتی از این دارو در افزایش پلاکت بیماران مبتلا به itp گزارش شده است.

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید